Prozac

Prozac (fluoxetine) is the most-studied SSRI in children and adolescents, but the evidence for its use still has important limits you should know about.

The data on Prozac comes almost entirely from manufacturer-funded trials that compare it to placebo or other drugs, never to no treatment at all in the long term. The 2013 meta-analysis of SSRIs for chronic depression and dysthymia found both drug classes beat placebo, with SSRIs better tolerated [7]. But that is the typical design: short-term, placebo-controlled, industry-funded. The longest pediatric trial in the evidence followed children for only six months after initial response, and even then, 42% of kids on Prozac still relapsed [21]. The same study reported one suicide attempt in the Prozac group [21].

The biggest safety signal is age-dependent. The FDA's own patient-level meta-analysis of nearly 100,000 people across 372 trials found that under age 25, antidepressants increase the risk of suicidal thoughts and behaviors [17]. For fluoxetine specifically, the odds ratio in adults was 0.71 (95% CI 0.52-0.99) for suicidal ideation, meaning it may reduce risk in that group [17]. But for children and adolescents, the black box warning exists for good reason: the risk goes up. A separate 2010 study of over 20,000 young people found no significant differences in suicide attempt risk between fluoxetine and other SSRIs, but the baseline rate was 27 per 1,000 across the whole group [18].

Side effects are common and not trivial. In pooled data from clinical trials, nausea hit about 2 in 10 patients on Prozac vs 1 in 10 on placebo; insomnia 16% vs 9%; nervousness 14% vs 9%; anorexia 11% vs 2%; tremor 10% vs 4% [19]. The drug also causes sexual dysfunction and can trigger extrapyramidal symptoms like akathisia (a severe inner restlessness), which is particularly concerning in young people because it can look like worsening anxiety and is linked to suicide risk [16].

The mechanism data is thin and mostly from animal studies. A 2015 mouse study showed fluoxetine causes acute anxiety in young mice by overstimulating 5-HT1A autoreceptors, and blocking those receptors reversed the effect [22]. This offers a plausible biological explanation for the clinical observation that some kids get worse before they get better, and for the FDA suicidality signal. But it is a mouse study, not human data.

The benefit in children is real but modest. The discontinuation trial found that continuing Prozac after initial improvement reduced relapse from 69% on placebo to 42% on drug, and cut full relapse from 48% to 22% [21]. That is a meaningful difference, but it means more than 1 in 5 kids still relapsed even while staying on the drug.

My call: Prozac has more pediatric evidence than any other antidepressant and clearly helps some children, but the benefit is modest, adverse effects are common, and the FDA's own data shows genuine increased suicide risk under age 25. For any child or adolescent, the decision requires informed consent that includes these numbers, close monitoring in the first weeks, and a plan for gradual discontinuation. Confidence: moderate.